RECOVERY & TISSUE REPAIR / COMPARE
Blends and Singles, Side by Side
Where the four repair entries converge, where they diverge, and how far the evidence behind each one actually reaches.
The short version
This page lines up KLOW, Wolverine, BPC-157 and TB-500 on the dimensions that matter most when reading research peptides: what kind of molecule or formulation each one is, where it has been studied most, how strong that evidence is, how it was administered in studies, regulatory and anti-doping standing, and its single biggest caution.
The headline: all four are studied for recovery and tissue repair, but they are at very different evidence stages. KLOW and Wolverine are blends — no controlled combination study exists for either. BPC-157 has the deepest single-component animal record plus three small human pilots. TB-500's evidence largely belongs to the larger parent protein it fragments. None is an approved medicine. None is presented here with a human dose.
The comparison matrix
| Dimension | KLOW | Wolverine | BPC-157 | TB-500 |
|---|---|---|---|---|
| Peptide class | 4-component research blend (KPV 3aa + GHK-Cu 3aa + BPC-157 15aa + TB-500 7aa) | 2-component research blend (BPC-157 15aa + TB-500 7aa) | Stable gastric pentadecapeptide (15aa) | Synthetic actin-binding heptapeptide fragment of thymosin beta-4 (7aa) |
| Most-studied in | Component literature: gut, skin, tendon, wound (no blend study) | Component literature: angiogenesis + cell migration (no blend study) | Tendon, gut, muscle and nerve repair; angiogenesis | Actin biology; cell migration and wound healing (mostly full-length Tβ4) |
| Evidence base (model) | Individual components in rodents/cells; no controlled blend study [1] | Individual components in rodents/cells; no controlled blend study [8] | Mostly rat; 3 small human pilots [9] | Mostly full-length Tβ4 in animals; 1 human Phase 1 (full-length Tβ4) [1][15] |
| Administration studied | Components: IM, IP, topical, oral (no formal blend PK) | Components: IM, IV pilot, IP (no formal blend PK) [2][12] | IM, intragastric, drinking water, IV pilot [2][12] | IV (full-length Tβ4), IP in animals [14][15] |
| Regulatory / WADA | Not approved; WADA: TB-500/Tβ4 = S2 prohibited, BPC-157 = S0 prohibited [1] | Not approved; WADA: BPC-157 = S0 prohibited, TB-500/Tβ4 = S2 prohibited [1][8] | Not approved; WADA S0 prohibited [1] | Not approved; WADA-prohibited (peptide/growth-factor) [1] |
| Key caution | No blend study; untested combination; TB-500 WADA-prohibited; pro-angiogenic caution in cancer [1] | No combination study; TB-500 identity gap; preclinical-only human record [8][11] | Single-lab, preclinical-heavy; 3 tiny human pilots; very short half-life [9][12] | Fragment vs full-protein identity gap; non-monotonic dose-response; no fragment human trials [1][14] |
Peptide class
The four span a structural range from blends to singles. KLOW is the most composite — a four-component co-formulation with masses ranging from a 3-amino-acid tripeptide (KPV, GHK-Cu) to a 15-amino-acid pentadecapeptide (BPC-157) and a 7-amino-acid acetylated fragment (TB-500). Wolverine is the two-component subset of KLOW, pairing just BPC-157 and TB-500. BPC-157 is the largest individual peptide at 15 amino acids, a stable gastric pentadecapeptide. TB-500 is the smallest at 7 amino acids — but it is a fragment, and the majority of its cited evidence comes from the much larger (~4963 Da) full-length thymosin beta-4 [11].
Most-studied in
Each entry has a home territory reflecting its proposed mechanisms. KLOW as a blend has no dedicated study territory — its research record is borrowed entirely from four individual components: gut and immune tissue (KPV), skin and matrix (GHK-Cu), tendon and vascular tissue (BPC-157), and cytoskeletal dynamics (TB-500/Tβ4). Wolverine inherits the same BPC-157 and TB-500 literature. BPC-157 as a single compound has the broadest animal record — tendon, gut, muscle, nerve — unified by angiogenesis [10]. TB-500 / thymosin beta-4 research centers on actin biology and the cell migration, angiogenesis and wound healing that follow from it [11].
Evidence base (model)
This is where the four genuinely separate. KLOW and Wolverine share the same baseline: component data only, no controlled blend study [1][8]. BPC-157 has the deepest individual animal record — three decades, multiple tissue types — plus three small uncontrolled human pilots; a 2025 narrative review explicitly states only three such pilots exist and recommends treating it as investigational [9]. TB-500 is the most nuanced: a Phase 1 IV safety study in 40 volunteers used full-length thymosin beta-4, not the marketed 7-mer fragment [15]; the fragment itself has no completed controlled human trials [1]. Across all four, the honest summary is: animal-model promise, scarce human data, and no combination evidence.
Administration studied
Administration routes track the research questions. BPC-157 has been studied intramuscularly, intragastrically, in drinking water, and in a tiny intravenous human safety pilot; its very short elimination half-life (under 30 minutes) is established by formal PK/ADME work in rats and dogs [2][12]. TB-500 / full-length Tβ4 was dosed intravenously in the human Phase 1 study and intraperitoneally in the rat stroke dose-response [14][15]. For KLOW and Wolverine, administration routes are those of their individual components — no formal blend pharmacokinetic study exists for either formulation [1][8].
Regulatory / WADA status
None of the four is an FDA- or EMA-approved medicine for systemic human use. Both blends carry WADA implications: KLOW contains TB-500 (S2, peptide hormones/growth factors, prohibited at all times) and BPC-157 (S0, non-approved substances, prohibited at all times); Wolverine contains both of those same two [1][8]. BPC-157 standalone is WADA S0 prohibited [1]. TB-500 standalone is prohibited under peptide/growth-factor categories and has been detected as a doping agent in racehorses [1]. For any individual subject to anti-doping rules, all four entries on this desk are off-limits.
Key caution
Each entry has a defining constraint. For KLOW it is the absence of any blend study combined with an inherent pharmacokinetic mismatch — the tripeptides clear far faster than BPC-157, which itself clears in under 30 minutes — meaning a co-formulated vial cannot deliver matched exposures [1][12]. For Wolverine it is the TB-500 identity gap: the marketed fragment is not the molecule behind most of the Tβ4 efficacy literature [8][11]. For BPC-157 it is the single-lab concentration of the foundational preclinical literature, with only three tiny human pilots and no long-term safety data [9]. For TB-500 it is the combination of the fragment identity gap and a non-monotonic dose-response in animals — where a higher dose produced less benefit than a lower one [14]. Reading all four together, the message is consistent: mechanistically plausible signals, early and mostly preclinical evidence, and no controlled human combination data at all.